Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06

IF 2.1 4区医学 Q3 HEMATOLOGY

Leukemia research Pub Date : 2025-04-20 DOI:10.1016/j.leukres.2025.107702

Gianluca Cavallaro , Silvia Salmoiraghi , Roberta Cavagna , Chiara Pavoni , Clara Belotti , Martina Milani , Elena Oldani , Marco Frigeni , Tamara Intermesoli , Anna Grassi , Renato Bassan , Orietta Spinelli , Alessandro Rambaldi , Federico Lussana

{"title":"Clinical impact of tyrosine kinases related mutations in NPM1 mutated acute myeloid leukaemia: A report from the Northern Italy Leukaemia Group (NILG) multicentre randomized trial 02/06","authors":"Gianluca Cavallaro , Silvia Salmoiraghi , Roberta Cavagna , Chiara Pavoni , Clara Belotti , Martina Milani , Elena Oldani , Marco Frigeni , Tamara Intermesoli , Anna Grassi , Renato Bassan , Orietta Spinelli , Alessandro Rambaldi , Federico Lussana","doi":"10.1016/j.leukres.2025.107702","DOIUrl":null,"url":null,"abstract":"<div><div>Co-mutational patterns play a role in the clinical outcome of nucleophosmin-1 (<em>NPM1</em>) mutated acute myeloid leukaemia (AML). Tyrosine kinase (TK) related gene mutations are included in these additional mutations, but their impact on prognosis of <em>NPM1</em>-mutated AML is unknown. We analyzed the outcomes of patients with <em>NPM1</em> AML with TK related mutations treated with intensive chemotherapy in the prospective randomized trial NILG AML 02/06, with regards to <em>NPM1-FLT3-ITD</em> and <em>NPM1</em>-isolated. Data show that additional TK related mutations do not impact the favorable prognosis on <em>NPM1-</em>mutated AML, unlike <em>NPM1-FLT3-ITD</em> mutated AML, for which consolidation with allogeneic stem cell transplantation should be considered for all young and fit patients in first complete remission.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"153 ","pages":"Article 107702"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212625000621","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Co-mutational patterns play a role in the clinical outcome of nucleophosmin-1 (NPM1) mutated acute myeloid leukaemia (AML). Tyrosine kinase (TK) related gene mutations are included in these additional mutations, but their impact on prognosis of NPM1-mutated AML is unknown. We analyzed the outcomes of patients with NPM1 AML with TK related mutations treated with intensive chemotherapy in the prospective randomized trial NILG AML 02/06, with regards to NPM1-FLT3-ITD and NPM1-isolated. Data show that additional TK related mutations do not impact the favorable prognosis on NPM1-mutated AML, unlike NPM1-FLT3-ITD mutated AML, for which consolidation with allogeneic stem cell transplantation should be considered for all young and fit patients in first complete remission.

查看原文本刊更多论文

酪氨酸激酶相关突变对NPM1突变急性髓性白血病的临床影响：一项来自意大利北部白血病组（NILG）多中心随机试验的报告

共突变模式对核糖蛋白-1（NPM1）突变型急性髓性白血病（AML）的临床预后有一定影响。酪氨酸激酶（TK）相关基因突变包括在这些额外突变中，但它们对NPM1突变急性髓性白血病预后的影响尚不清楚。我们分析了在前瞻性随机试验 NILG AML 02/06 中接受强化化疗的 NPM1 AML 伴 TK 相关基因突变患者的预后，包括 NPM1-FLT3-ITD 和 NPM1-隔离。数据显示，额外的TK相关突变不会影响NPM1突变型急性髓细胞性白血病的良好预后，而NPM1-FLT3-ITD突变型急性髓细胞性白血病则不同，对于所有首次完全缓解的年轻且体格健壮的患者，应考虑通过异基因干细胞移植进行巩固治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia research 医学-血液学

CiteScore

4.00

自引率

3.70%

发文量

259

审稿时长

1 months

期刊介绍： Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.